Loading
Primmune Therapeutics is a San Diego biotech whose oral TLR7 agonist PRTX007 activates the innate immune system in short daily pulses to fight solid tumours and viral infections.
Primmune Therapeutics develops orally available small-molecule agonists of Toll-like receptor 7 designed to give brief, controlled pulses of interferon and innate immune activation rather than the sustained cytokine release that limits injected agonists. PRTX007 has been studied in healthy volunteers and in patients with advanced solid tumours, and a related programme has been tested in viral disease.
PRTX007 is a small-molecule inhibitor from Primmune Therapeutics, Inc., in registered phase 2 trials for melanoma.